靶向治疗

跳转到: 导航, 搜索

靶向治疗靶向分子治疗是一种以干扰癌变肿瘤增生所需的特定分子来阻止癌细胞增长的一种药物疗法[1]而非一般的干扰所有持续分裂细胞(不稳定细胞)的传统化疗法放射疗法尽管是针对特定肿瘤的,但是并非此处“靶向”的含义。

癌症靶向治疗在被认为是比当今其他疗法更加有效,并且对正常细胞伤害更小的疗法。

靶向治疗可以治疗乳腺癌多发性骨髓癌淋巴癌前列腺癌黑色素瘤以及其他一些癌症。[2]

Mark Greene在1985年报告,确切的实验(在体内和体外环境用单克隆抗体处理Her2/neu软化细胞)表明靶向治疗会逆转肿瘤细胞恶性表型[3]

一些人拒绝接受靶向治疗这个术语所指的药物是没有选择性的这种观点。[4]“靶向治疗”这个术语有时在文章中,会带双引号出现。[5]

目录

种类

靶向治疗可分为小分子,小分子偶联物,单克隆抗体三大类。

小分子

伊马替尼的机理 大多是酪氨酸激酶抑制剂(TKI)。

小分子偶联物

单克隆抗体

一些单克隆抗体正在发展,少数已获得FDA的批准。以下是一些得到许可的单克隆抗体:

有许多抗体偶联物正在研发,请参见抗体导向酶前药治疗(ADEPT)。

进展与未来发展

在美国,美国国家癌症研究所Molecular Targets Development Program (MTDP,分子靶点发展计划)致力于研究可能对药物发展有帮助的分子靶点。

参考文献

  1. Definition of targeted therapy - NCI Dictionary of Cancer Terms. 
  2. NCI: Targeted Therapy tutorials
  3. Perantoni AO, Rice JM, Reed CD, Watatani M, Wenk ML. [http//www.ncbi.nlm.nih.gov/pmc/articles/PMC299062/ Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea]. Proc. Natl. Acad. Sci. U.S.A.. September 1987, 84 (17): 6317–6321. doi:10.1073/pnas.84.17.6317. PMID 3476947. PMC 299062. 
    Drebin JA, Link VC, Weinberg RA, Greene MI. [http//www.ncbi.nlm.nih.gov/pmc/articles/PMC387088/ Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen]. Proc. Natl. Acad. Sci. U.S.A.. December 1986, 83 (23): 9129–9133. doi:10.1073/pnas.83.23.9129. PMID 3466178. PMC 387088. 
    Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. July 1985, 41 (3): 697–706. doi:10.1016/S0092-8674(85)80050-7. PMID 2860972. 
  4. Zhukov NV, Tjulandin SA. Targeted therapy in the treatment of solid tumors: practice contradicts theory. Biochemistry Mosc.. May 2008, 73 (5): 605–618. doi:10.1134/S000629790805012X. PMID 18605984. 
  5. Markman M. The promise and perils of 'targeted therapy' of advanced ovarian cancer. Oncology. 2008, 74 (1–2): 1–6. doi:10.1159/000138349. PMID 18536523. 
  6. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol. January 2009, 2 (1): 2. doi:10.1186/1756-8722-2-2. PMID 19159467. PMC 2637898. 
  7. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur. J. Cancer. January 2008, 44 (1): 30–38. doi:10.1016/j.ejca.2007.11.002. PMID 18068350. PMC 2566958. 
  8. Warr MR, Shore GC. Small-molecule Bcl-2 antagonists as targeted therapy in oncology. Curr Oncol. December 2008, 15 (6): 256–61. PMID 19079626. PMC 2601021. 
  9. Li J, Zhao X, Chen L, et al.. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010, 10: 529. doi:10.1186/1471-2407-10-529. PMID 20923544. PMC 2984425. 
  10. http://clinicaltrials.gov/ct2/results?term=apatinib
  11. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.. 
  12. http://www.dddmag.com/news/2012/04/merck-endocyte-development-deal
  13. Pollack, Andrew. F.D.A. Panel Supports Avastin to Treat Brain Tumor. New York Times. 2009-03-31 [2009-08-13]. 

外部链接

参考来源

关于“靶向治疗”的留言: Feed-icon.png 订阅讨论RSS

目前暂无留言

添加留言
个人工具
名字空间
动作
导航
推荐工具
功能菜单
工具箱